13价肺炎球菌结合疫苗对有风险状况老年人疫苗型社区获得性肺炎疗效的事后分析
基于CAPiTA随机双盲安慰剂对照试验的事后分析,纳入84,496名≥65岁成人,其中41,385名(49.2%)因慢性疾病被归为有风险状况。有风险参与者中PCV13对首次疫苗型社区获得性肺炎的疫苗效力为40.3%(95.2%CI:11.4%,60.2%),平均随访3.95年期间保护未减弱。
要点
- 有风险状况老年人中PCV13对首次疫苗型社区获得性肺炎的疫苗效力为40.3%(95.2%CI:11.4%,60.2%)。
- 139例疫苗型社区获得性肺炎中115例(82.7%)发生于有风险状况参与者。
- 有风险参与者平均随访3.95年,研究期间保护未减弱。
核心结论
- 这项CAPiTA事后分析显示,PCV13对有风险状况老年人疫苗型社区获得性肺炎具有显著且持久的效力。
研究设计与样本
- CAPiTA为在荷兰开展的双盲、平行组、随机、安慰剂对照研究,≥65岁成人接受PCV13或安慰剂。
- 本分析为事后分析,依据自我报告的慢性疾病(心脏病、肺病、哮喘、糖尿病、肝病和吸烟)将参与者分为有风险状况。
- 入组84,496名成人,其中41,385名(49.2%)因慢性疾病被归为有风险状况。
主要发现
- 139例疫苗型社区获得性肺炎中,115例(82.7%)发生于有风险状况参与者。
- 有风险状况参与者中PCV13对首次疫苗型社区获得性肺炎的疫苗效力为40.3%(95.2%CI:11.4%,60.2%)。
- 有风险参与者自接种疫苗以来平均随访3.95年,研究期间保护未减弱。
关键数值与推荐
- 有风险状况参与者中PCV13对首次疫苗型社区获得性肺炎的疫苗效力为40.3%(95.2%CI:11.4%,60.2%)。
- 139例疫苗型社区获得性肺炎中115例(82.7%)发生于有风险状况参与者。
- 有风险参与者平均随访3.95年,保护未减弱。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with certain chronic medical conditions are at higher risk of developing pneumonia and pneumococcal disease than those without. Using data from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), this post hoc analysis assessed the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥65 years with at-risk conditions. METHODS: The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) was a double-blind, parallel-group, randomized, placebo-controlled study in the Netherlands in which adults aged ≥65 years received either PCV13 or placebo. Outcomes of interest were identified using prespecified clinical criteria, radiographic confirmation, routine microbiologic testing, and a serotype-specific urinary antigen detection assay. In this post hoc analysis, participants were classified by at-risk status based on self-reporting of any of the following chronic medical conditions: heart disease, lung disease, asthma, diabetes, liver disease, and smoking. The objective of this analysis was to assess PCV13 vaccine efficacy (VE) against a first episode of vaccine-serotype community-acquired pneumonia (VT-CAP) in at-risk participants. RESULTS: Of the 84,496 adults enrolled in the study, 41,385 (49.2%) were considered at risk owing to chronic medical conditions. Of the 139 VT-CAP cases, 115 (82.7%) occurred in these participants. VE of PCV13 against a first episode of VT-CAP among participants with at-risk conditions was 40.3% (95.2% CI: 11.4%, 60.2%). Average duration of follow-up since vaccination was 3.95 years for at-risk participants; protection did not wane over the study period. CONCLUSIONS: This post hoc analysis of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) showed significant and persistent efficacy of PCV13 against VT-CAP in at-risk older adults. ClinicalTrials.gov identifier: NCT00744263.
引用
- Suaya JA, Jiang Q, Scott DA, et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 2018. PMID: 29429807. doi:10.1016/j.vaccine.2018.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。